Page last updated: 2024-08-21

chenodeoxycholic acid and Metabolic Syndrome

chenodeoxycholic acid has been researched along with Metabolic Syndrome in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's8 (80.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Abraham, DJ; Lin, HR1
Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y1
Aguilera, V; Ampuero, J; Bellido, F; Romero-Gómez, M; Sánchez-Torrijos, Y1
Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L1
Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Maggi, M; Maneschi, E; Marini, M; Morelli, A; Persani, L; Rastrelli, G; Sarchielli, E; Vannelli, GB; Vignozzi, L1
Adorini, L; Cellai, I; Comeglio, P; Filippi, S; Galli, A; Maggi, M; Maneschi, E; Mannucci, E; Morelli, A; Rastrelli, G; Saad, F; Sarchielli, E; Vannelli, GB; Vignozzi, L1
Alawad, AS; Levy, C1
Costa, SM; Couto, CA; Lisboa, QC1
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Piccinni, MP; Saad, F; Sarchielli, E; Serni, S; Vannelli, GB; Vignozzi, L1
Adorini, L; Carini, M; Cellai, I; Comeglio, P; Filippi, S; Gacci, M; Maggi, M; Maneschi, E; Morelli, A; Sarchielli, E; Vannelli, GB; Vignozzi, L; Yehiely-Cohen, R1

Reviews

4 review(s) available for chenodeoxycholic acid and Metabolic Syndrome

ArticleYear
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
    Journal of medicinal chemistry, 2020, 05-28, Volume: 63, Issue:10

    Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary

2020
New therapeutic perspectives in non-alcoholic steatohepatitis.
    Gastroenterologia y hepatologia, 2018, Volume: 41, Issue:2

    Topics: Bariatric Surgery; Chenodeoxycholic Acid; Clinical Trials as Topic; Combined Modality Therapy; Diet, Mediterranean; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Dyslipidemias; Endoscopy; Exercise Therapy; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; MAP Kinase Kinase Kinase 5; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Weight Loss

2018
Nonalcoholic fatty liver disease: Evolving paradigms.
    World journal of gastroenterology, 2017, Sep-28, Volume: 23, Issue:36

    Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E

2017
FXR Agonists: From Bench to Bedside, a Guide for Clinicians.
    Digestive diseases and sciences, 2016, Volume: 61, Issue:12

    Topics: Animals; Azepines; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholestasis; Drug Evaluation, Preclinical; Gastrointestinal Agents; Hepatitis, Autoimmune; Humans; Hypertension, Portal; Indoles; Isoxazoles; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Diseases; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid

2016

Other Studies

6 other study(ies) available for chenodeoxycholic acid and Metabolic Syndrome

ArticleYear
Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents.
    Bioorganic & medicinal chemistry letters, 2006, Aug-15, Volume: 16, Issue:16

    Topics: Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Chenodeoxycholic Acid; DNA-Binding Proteins; Drug Design; Genes, Reporter; Humans; Metabolic Syndrome; Models, Chemical; Models, Molecular; Neoplasms; Protein Binding; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transcriptional Activation; Transfection; Two-Hybrid System Techniques

2006
Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits.
    Molecular and cellular endocrinology, 2014, Jan-25, Volume: 382, Issue:1

    Topics: Animals; Antibodies, Monoclonal; Biomarkers; Chenodeoxycholic Acid; Diet, High-Fat; Gene Expression Regulation; Glucose Transporter Type 4; Gonadotropin-Releasing Hormone; Immunohistochemistry; Inflammation; Infliximab; Male; Metabolic Syndrome; Neurons; Preoptic Area; Rabbits; Receptors, G-Protein-Coupled; RNA, Messenger

2014
Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit.
    Molecular and cellular endocrinology, 2014, Mar-25, Volume: 384, Issue:1-2

    Topics: Acetylcholine; Animals; Antibodies, Monoclonal; Chenodeoxycholic Acid; Diet, High-Fat; Dietary Fats; Erectile Dysfunction; Fatty Liver; Gene Expression; Humans; Imidazoles; Infliximab; Liver; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Rabbits; Receptors, Cytoplasmic and Nuclear; Sulfones; Testosterone; Triazines; Tumor Necrosis Factor-alpha; Vardenafil Dihydrochloride

2014
Current management of non-alcoholic fatty liver disease.
    Revista da Associacao Medica Brasileira (1992), 2016, Volume: 62, Issue:9

    Topics: Bariatric Surgery; Chenodeoxycholic Acid; Diet, Healthy; Exercise; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease

2016
Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
    The Journal of endocrinology, 2012, Volume: 212, Issue:1

    Topics: Androgens; Animals; Biomarkers; Chenodeoxycholic Acid; Dietary Fats; Disease Models, Animal; Drug Evaluation, Preclinical; Estradiol; Fibrosis; Male; Metabolic Syndrome; Prostate; Prostatitis; Rabbits; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger; Testosterone

2012
Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
    The Journal of steroid biochemistry and molecular biology, 2012, Volume: 132, Issue:1-2

    Topics: Androgens; Animals; Blood Glucose; Cell Movement; Chenodeoxycholic Acid; Cholesterol; Diet, High-Fat; Disease Models, Animal; Hypogonadism; Male; Metabolic Syndrome; Muscle Contraction; Myocytes, Smooth Muscle; Prostate; Rabbits; Receptors, Androgen; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Testosterone; Triglycerides; Triptorelin Pamoate; Urinary Bladder

2012